Researchers found that the FDA has approved a new treatment called Tudriqev for patients with advanced melanoma that has not responded to previous therapies. This genetically modified viral therapy, which is injected directly into tumors, works by targeting and destroying cancer cells while also stimulating the immune system to fight the cancer. When combined with another immunotherapy drug, nivolumab, it offers hope for individuals facing a particularly tough battle against this aggressive skin cancer.

This approval is significant for people with advanced melanoma, especially those who have exhausted other treatment options. In clinical trials, about 24% of participants experienced a positive response to Tudriqev, with these responses lasting an average of 14 months. For patients who often face a grim prognosis, this new option could mean a longer life and improved quality of health during treatment.

The evidence supporting Tudriqev comes from a clinical trial involving 140 adults with advanced melanoma who had not responded to at least eight weeks of prior anti-PD-1 therapy. While the results are promising, it’s important to note that the therapy was granted accelerated approval based on early findings, and further trials are required to confirm its long-term effectiveness and safety. Patients should be aware that common side effects include fatigue, fever, and infections, and there are important safety warnings regarding the potential spread of the herpes virus used in the treatment.

For those interested in the latest cancer therapies, staying informed about new treatments like Tudriqev could be vital. If you or someone you know is dealing with advanced melanoma, discussing this new option with a healthcare provider may be beneficial.

Source